Alpha Sense BI

FEBRUARY 8, 2023

Attracting industry leaders, emerging fast-growth companies, and technology creators from around the world, life science corporations share their latest advances, leading research, and best practices — as well as their intentions to scale their digital health solutions — to the masses in hopes of securing capital.

Biotech 96

Biotech Research Innovation Capital 96

Alpha Sense BI

APRIL 29, 2024

Heading into the second half of 2024, venture capital investors remain cautious as they acknowledge persistent challenging dynamics in the landscape. While dry powder reserves have reached record highs, investors are wary about deploying capital with certain recent macroeconomic factors still fresh in mind.

Capital 52

Capital Due Diligence Biotech Startups 52

Alpha Sense BI

APRIL 19, 2024

2020 and 2021 were marked by increased innovation, accelerated growth, and workforce expansion. On the other hand, 2022 and 2023 brought mass layoffs , falling market capitalizations, and a weakening of global tech spending. Over the past few years, the technology industry has experienced dramatic highs and lows.

Technology 69

Technology Technology Retail Biotech 69

Alpha Sense BI

JANUARY 26, 2024

Attracting industry leaders, emerging fast-growth companies, and technology creators from around the world, life science corporations share their latest advances, leading research, and best practices—as well as their intentions to scale their digital health solutions—to the masses in hopes of securing capital.

Biotech 59

Biotech Research Loss Algorithm 59

Alpha Sense BI

MARCH 13, 2024

billion acquisition of Carmot Therapeutics, a clinical-stage biotechnology company with three GLP-1 assets in clinical production, including its CT-388 lead GLP-1 asset, in the hopes of gaining a competitive footing among Novo Nordisk and Eli Lilly’s products currently on the market (Ozempic, Wegovy, and Mounjaro, respectively).

Pharmaceutical 59

Pharmaceutical Hospitals Due Diligence Biotech 59